| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| POTASSIUM CITRATE (Paeds) (K-Citra 10; K-Lyte) Mechanism of action: Electrolyte replacement. Ref: 4, 44, 575 Last update: 2022-09-09 |
Liquid (K-Citra 10 solution): each milliliter provides 2 mmol of K+ and 2 mmol of bicarbonate equivalent. Tablets: Effervescent (K-Lyte): each tablet provides 25 mmol K+ and 25 mmol of bicarbonate equivalent. Slow Release (K-Citra 10): each 1080 mg tablet provides 10 mmol K+ and 10 mmol of bicarbonate equivalent. |
*doses expressed as mmol bicarbonate Urinary alkalinization: Children: 0.25-1 mmol/kg/dose PO QID; titrate to desired urinary pH Adults: 20-30 mmol PO QID Acidosis of chronic renal failure: 0.25-1 mmol/kg/day TID-QID Renal tubular acidosis, Distal (Type 1): Children: 0.5-1 mmol/kg/dose BID-QID Adults: 0.125-0.5 mmol/kg/dose BID-QID Renal tubular acidosis: Proximal (Type 2): Children and Adults: initial: 1-2.5 mmol/kg/dose BID-QID; titrate to maintain serum bicarbonate in the normal range. |
Used in children with renal disease who require bicarbonate but cannot tolerate the sodium load from sodium bicarbonate or are persistently hypokalemic. K-Lyte effervescent tablets must be dissolved in water or juice prior to administration (at least 100 mL). Dilute potassium citrate liquid solution in water or juice to improve palatability (chilling also improves taste). Give with food or meals to decrease adverse GI effects. Limit single dose to 20 mmol per dose to minimize risk of GI adverse effects. Standard Prescription: potassium citrate __mEq PO ___(frequency) (__mEq/kg/24 hr) |